VINC Live signaler | Maksimer profitt med Getagraph.com

Live Chart Being Loaded With Signals

Commentary (26 apr 2024 @ 22:00):

Vincerx Pharma, Inc., a clinical-stage biopharmaceutical company, researches and develops therapies to address unmet medical needs for the treatment of cancer in the United States...

Stats
Dagens volum	1.72M
Gjennomsnittsvolum	1.18M
Markedsverdi	15.63M
EPS	$0 ( 2024-03-26 )
Neste inntjeningsdato	( $-0.260 ) 2024-05-09
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.390
ATR14	$0.0120 (1.65%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-07	Izumi Raquel E.	Buy	123 750	Stock Option (right to buy)
2024-03-07	Seelenberger Alexander A.	Buy	93 750	Stock Option (right to buy)
2024-03-07	Hamdy Ahmed Md	Buy	146 746	Stock Option (right to buy)
2024-03-07	Thomas Tom C	Buy	93 750	Stock Option (right to buy)
2023-08-11	Seelenberger Alexander A.	Buy	10 500	Common Stock

INSIDER POWER
100.00
Last 97 transactions
Buy: 7 261 732 \| Sell: 1 766 942

Volum Korrelasjon

Lang: -0.44 (neutral)

Kort: -0.91 (very strong negative)

Signal:(31.431) Neutral

Vincerx Pharma, Inc. Korrelasjon

10 Mest positive korrelasjoner
SVAC	0.929
PAIC	0.909
RMRM	0.901
TLGT	0.894
MTSL	0.893
SVOK	0.862
MODV	0.861
CLMT	0.858
BOXL	0.842
ABNB	0.839

10 Mest negative korrelasjoner
AMRB	-0.955
NETE	-0.938
MMAC	-0.917
RAVN	-0.869
SRAC	-0.86
SBBP	-0.859
LWAC	-0.855
MGPI	-0.841
BOCH	-0.836
SHSP	-0.808

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

Vincerx Pharma, Inc. Korrelasjon - Valuta/Råvare

-0.72
( moderate negative )

-0.77
( moderate negative )

0.00
( neutral )

0.16
( neutral )

Vincerx Pharma, Inc. Økonomi

Annual	2023
Omsetning:	$0
Bruttogevinst:	$-915 000 (0.00 %)
EPS:	$-1.890

FY	2023
Omsetning:	$0
Bruttogevinst:	$-915 000 (0.00 %)
EPS:	$-1.890

FY	2022
Omsetning:	$0
Bruttogevinst:	$-939 000 (0.00 %)
EPS:	$-2.72

FY	2021
Omsetning:	$0.00
Bruttogevinst:	$0.00 (0.00 %)
EPS:	$-7.48

Financial Reports:

No articles found.

Vincerx Pharma, Inc.

Vincerx Pharma, Inc., a clinical-stage biopharmaceutical company, researches and develops therapies to address unmet medical needs for the treatment of cancer in the United States. Its lead product candidate is VIP152, a cyclin-dependent kinase-9 inhibitor for treating patients with advanced cancer. The company's preclinical stage product candidates include VIP217, an oral PTEFb/CDK9 inhibitor; VIP236, a small molecule drug conjugate to treat solid tumors; and VIP943 and VIP924 for the treatment of hematologic malignancies. Vincerx Pharma, Inc. was founded in 2019 is headquartered in Palo Alto, California.